Abstract
Background:
Vitiligo is an autoimmune dermatological disease characterized by hypopigmented macules. Treatments include topical agents, phototherapy, and laser therapies. Different lasers should be individually chosen regarding location, extent, activity of the disease.
Aims:
This article aims to demonstrate how blue LED is effective and safe, as its wavelength is very close to the UV spectrum (415 nm vs. 400 nm), but, unlike UV therapy, blue LED have not shown any long-term cancerogenic side effects.
Patients/methods:
We treated 30 patients affected by vitiligo localized on different anatomical areas with blue light-emitting diodes.
Results:
Complete repigmentation occurred in 75.33% of treated patients (22 out of 30 patients, 14 males, and 8 females). Partial repigmentation occurred in the remaining patients.
Conclusions:
Blue LED light may be a safe and well-tolerated way to induce repigmentation in patients affected by vitiligo.
Full text
